X
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Novartis ianalumab Sjogrens trial

    Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

    EU Approval for Koselugo

    AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN

    Cancer Research

    Guardant Health, Zephyr AI Collab to Advance Cancer Research

    CDMO market growth trends

    Biobeat Report: CDMO Growth in China and USA for 2026

    Ulcerative Colitis

    FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis

    digital validation pharma

    Digital Validation and Compliance in Pharma

    green bioprocessing pharma

    Carbon-Neutral Bioprocessing in Pharmaceuticals

    precision fermentation biotech

    Precision Fermentation and the Future of Biomanufacturing

    cell therapy biotech

    Regenerative Medicine and Cell Therapy Innovations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Novartis ianalumab Sjogrens trial

    Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

    EU Approval for Koselugo

    AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN

    Cancer Research

    Guardant Health, Zephyr AI Collab to Advance Cancer Research

    CDMO market growth trends

    Biobeat Report: CDMO Growth in China and USA for 2026

    Ulcerative Colitis

    FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis

    digital validation pharma

    Digital Validation and Compliance in Pharma

    green bioprocessing pharma

    Carbon-Neutral Bioprocessing in Pharmaceuticals

    precision fermentation biotech

    Precision Fermentation and the Future of Biomanufacturing

    cell therapy biotech

    Regenerative Medicine and Cell Therapy Innovations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

In US, FedEx faces drug trafficking charges

Yuvraj_pawp by Yuvraj_pawp
31st July 2014
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The courier firm FedEx faces drug-trafficking charges after being indicted by a federal grand jury in California, in a case that highlights the growth in illegal online pharmacies selling dubious medication to people without prescription.

The 15-count indictment accuses FedEx of conspiring in the delivery of illicit pharmaceuticals, including the sleep aid Ambien and the slimming drug phendimetrazine, despite repeated warnings from the authorities.

During the period covered by the indictment, between 2000 and 2010, FedEx is alleged to have adopted special policies governing the dubious deliveries that would prevent its employees being penalized if a pharmacy closed for business. Prosecutors said the firm made some $820m (£480m) by turning a blind eye to the questionable trade.

US attorney Melinda Haag said, “The advent of internet pharmacies allowed cheap and easy distribution of illegal prescription drugs to every part of the US, while allowing perpetrators to conceal their identities… This indictment highlights the importance of holding corporations that knowingly enable illegal activity responsible for their role in aiding criminal behaviour.” Marjorie Clifton, the executive director of the not-forprofit Center for Safe Internet Pharmacies, said over 100,000 deaths a year are linked to prescription drugs that have been bought online.

Tags: AmericaFedEx faces drug trafficking charges
Previous Post

Eisai and Arena Pharmaceuticals Announce BELVIQ(R) (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category

Next Post

Meda agrees to acquire Rottapharm for €2.3bn

Related Posts

EU Approval for Koselugo
Drug Development

AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN

31st October 2025
Cancer Research
Drug Development

Guardant Health, Zephyr AI Collab to Advance Cancer Research

30th October 2025
Ulcerative Colitis
Americas

FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis

29th October 2025
Avidity Biosciences
Americas

Novartis to Acquire Avidity Biosciences in $12 Billion Deal

28th October 2025
manufacturing facility
Americas

AstraZeneca Unveils Expanded Manufacturing Facility in Texas

28th October 2025
GLP1 therapy
Americas

FDA Approves Novo Nordisk’s Rybelsus Oral GLP-1 Therapy

27th October 2025
Next Post

Pfizer to acquire Baxter’s portfolio of marketed vaccines for $635m

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In